BioSpace News Archive

Net sales of $109.1 million, an increase of 0.4% compared to prior year and 1.9% on a constant currency basis

Aflac Incorporated announced that Max K. Brodén has been named senior vice president; deputy chief financial officer and treasurer of Aflac Incorporated, reporting to Aflac Incorporated Executive Vice President and Chief Financial Officer Frederick J. Crawford.

Cash Balance of $205 Million at March 31, After Purchases of $24 Million of Term Loans

CannTrust Holdings Inc. announced the closing of its previously-announced underwritten public offering of 36,363,636 common shares at a price to the public of US$5.50 per share.

Magenta Therapeutics, Inc. announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $13.25 per share.

Masimo announced its financial results for the first quarter ended March 30, 2019.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter of 2019, meeting its outlook for net sales growth at constant exchange rates, or CER, and exceeding the outlook for adjusted earnings per share at CER while driving global expansion of its Sample to Insight portfolio of molecular testing solutions.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock

Lisa Earnhardt to Step Down as CEO, Will Remain on Board of Directors

Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019.